Towards personalized tumor markers.
Ontology highlight
ABSTRACT: The cancer biomarker discovery pipeline is progressing slowly. The difficulties of finding novel and effective biomarkers for diagnosis and management of cancer patients are well-known. We speculate that it is unlikely to discover new serological biomarkers characterized by high sensitivity and specificity. This projection is supported by recent findings that cancers are genetically highly heterogeneous. Here, we propose a new way of improving the landscape of cancer biomarker research. There are currently hundreds, if not thousands, of described biomarkers which perform at high specificity (> 90%), but at relatively low sensitivity (< 30%). We call these "rare tumor markers." Borrowing from the principles of precision medicine, we advocate that among these low sensitivity markers, some ma
SUBMITTER: Kulasingam V
PROVIDER: S-EPMC5871887 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
ACCESS DATA